<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413269</url>
  </required_header>
  <id_info>
    <org_study_id>CH-BC-013</org_study_id>
    <nct_id>NCT01413269</nct_id>
  </id_info>
  <brief_title>Randomized Study of Hypofractionated and Conventional Fractionation Radiotherapy After Breast Conservative Surgery</brief_title>
  <official_title>Phase 3 Open-labeled Randomized Clinical Study of Comparing Hypofractionated and Conventional Radiotherapy for Breast Cancer Patients After Breast Conservative Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early-stage breast cancer patients treated with breast conservative surgery are enrolled in&#xD;
      this study if they meet defined criteria. Patients are randomized into two groups:&#xD;
      conventional fractionation radiotherapy and hypofractionated radiotherapy.The hypothesis is&#xD;
      that conventional fractionation radiotherapy and hypofractionated radiotherapy have similar&#xD;
      efficacy and toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in-breast recurrence rate</measure>
    <time_frame>5 year</time_frame>
    <description>evidence of ipsilateral breast local recurrence confirmed by histology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>regional node recurrence rate</measure>
    <time_frame>5 year</time_frame>
    <description>ipsilateral axillary node, internal mammary node and supraclavicular node recurrence confirmed by physical examination, image evaluation or histology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 year</time_frame>
    <description>locoregional relapse, distant relapse, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 year</time_frame>
    <description>any death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>radiation dermatitis and radiation pneumonitis evaluated and graded by CTC3.0 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late complication</measure>
    <time_frame>3 -10 year</time_frame>
    <description>breast cosmetic effect, ischemic heart disease, rib fracture, arm edema and shoulder joint dysfunction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">720</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>hypofractionation radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irradiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional fractionation radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>irradiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.&#xD;
the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.</description>
    <arm_group_label>conventional fractionation radiotherapy</arm_group_label>
    <arm_group_label>hypofractionation radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. KPS&gt;=60&#xD;
&#xD;
          2. histology confirmed invasive breast cancer&#xD;
&#xD;
          3. received breast conservative surgery(wide local excision and axilla dissection, or&#xD;
             axillary sentinel node biopsy if sentinel node is negative)&#xD;
&#xD;
          4. surgical margins negative&#xD;
&#xD;
          5. primary tumor ≤5cm in the largest diameter&#xD;
&#xD;
          6. no internal mammary node or supraclavicular node metastases or distant metastasis&#xD;
&#xD;
          7. can tolerate chemotherapy,hormone therapy (if needed) and radiotherapy&#xD;
&#xD;
          8. for patients not need chemotherapy，enrollment date is required no more than 8 weeks&#xD;
             from surgery date&#xD;
&#xD;
          9. for patients with chemotherapy first,enrollment date is required no more than 8 weeks&#xD;
             from the last date of chemotherapy&#xD;
&#xD;
         10. patients signed written inform consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ductal carcinoma in situ&#xD;
&#xD;
          2. prior neoadjuvant chemotherapy&#xD;
&#xD;
          3. prior breast cancer history&#xD;
&#xD;
          4. bilateral breast cancer&#xD;
&#xD;
          5. pregnant or during lactation&#xD;
&#xD;
          6. prior or concomitant malignant tumor excluded skin cancer(not malignant melanoma) and&#xD;
             cervix carcinoma in situ&#xD;
&#xD;
          7. active collagen vascular disease&#xD;
&#xD;
          8. prior neoadjuvant hormone therapy&#xD;
&#xD;
          9. immediate ipsilateral breast reconstruction&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ye-xiong Li, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shu-lian Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hang-zhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shu lian Wang</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>breast cancer patients</keyword>
  <keyword>breast conservation surgery</keyword>
  <keyword>hypofractionated radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

